Phase
Condition
Atopic Dermatitis
Dermatitis, Atopic
Eczema (Atopic Dermatitis)
Treatment
BBT001
Placebo
Clinical Study ID
Ages 18-65 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Key Inclusion Criteria ( Part A and B):
Age of 18-65 years.
Body mass index between 18-28 kg/m², capped at 120 kg.
Negative pregnancy tests for women of childbearing potential.
Willingness to refrain from alcohol consumption for 24 hours prior to each study visit.
Non-smokers, healthy current smokers (≤5 cigarettes/day), or ex-smokers.
Adequate contraception use (for men and women of childbearing potential).
No clinically significant abnormalities or history of relevant diseases.
Key Inclusion Criteria (Part B only):
Must have dermatologist-confirmed chronic atopic dermatitis (≥12 months). Inadequate response to topical treatments or where they are medically inadvisable.
Moderate to severe atopic dermatitis
Validated investigator's global assessment for atopic dermatitis (vIGA-ADTM) score ≥3
Atopic lesions cover ≥10% of body surface area (BSA)
Average peak pruritus numeric rating scale (PP-NRS) score ≥4 in the 7 days before randomization.
Eczema Area and Severity Index (EASI) score ≥16 at screening and randomization visits.
Key Exclusion Criteria for (Part A&B)
Significant health issues, such as: diabetes, positive tests for human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B surface antigen (HBsAg), immunodeficiencies, autoimmune diseases, or cancer, history of conditions predisposing to infections.
History of major metabolic, dermatological, liver, kidney, hematological, or other significant disorders.
Clinically relevant abnormal lab results, including low blood counts, liver issues, or abnormal kidney function.
Positive drug/alcohol tests or abnormal vital signs at screening or Day -1.
Abnormal Electrocardiogram (ECG) findings
History of drug/alcohol abuse in the past 2 years.
Donated >500mL blood within 2 months of screening.
History of severe allergic reactions or hypersensitivity.
Key Exclusion Criteria for (Part B only)
Skin diseases other than atopic dermatitis, significant tattoos, or scarring.
Receipt of immunoglobulin or blood products within 30 days.
Atopic dermatitis with ocular symptoms or chronic ocular steroid use.
Chronic pruritus from conditions other than atopic dermatitis.
Acute/treated infections or chronic skin infections.
Current use of sedating antihistamines or corticosteroids.
Study Design
Study Description
Connect with a study center
The Second Hospital of Anhui Medical Univesity
Hefei 1808722, Anhui 1818058 230601
ChinaActive - Recruiting
The Second Affiliated Hospital of Wannan Medical College
Wuhu 1791236, Anhui 1818058 241001
ChinaSite Not Available
Peking University People's Hospital
Beijing 1816670, Beijing Municipality 2038349 100032
ChinaSite Not Available
Dermatology Hospital of Southern Medical University
Guangzhou 1809858, Guangdong 1809935 510440
ChinaSite Not Available
The Second Xiangya Hospital of Central South University
Changsha 1815577, Hunan 1806691 410011
ChinaSite Not Available
Wuxi Second People's Hospital
Wuxi 1790923, Jiangsu 1806260 214002
ChinaSite Not Available
Jiangsu University Affiliated Hospital
Zhenjiang 1784642, Jiangsu 1806260 212001
ChinaSite Not Available
Jiangxi Provincial Dermatology Hospital
Nanchang 1800163, Jiangxi 1806222 330000
ChinaSite Not Available
Shandong Provincial Hospital for Skin Diseases
Jinan 1805753, Shandong 1796328 250011
ChinaSite Not Available
Shanghai Dermatology Hospital
Shanghai 1796236, Shanghai Municipality 1796231 200050
ChinaSite Not Available

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.